In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
News|Articles|October 25, 2023
Massive Bio, ONCOassist Launch Strategic Partnership
Collaboration to focus on enhancing physician engagement in clinical trials and cancer research.
Advertisement
Massive Bio and ONCOassist have announced in a joint press release that they have entered into a strategic partnership with the aim of optimizing patient-centric care and enhancing physician engagement in clinical trials and cancer research. As a result of the joint venture, the organizations are hoping to reshape the oncology landscape.
"In the rapidly evolving realm of oncology, our partnership with ONCOassist stands as a testament to our dedication to pushing the boundaries and ensuring every cancer patient receives optimal care,” said Arturo Loaiza-Bonilla, MD, co-founder, chief medical officer, Massive Bio, in the aforementioned press release.
Reference: Massive Bio and ONCOassist® Announce Strategic Partnership at ESMO 2023. BusinessWire. October 19, 2023. Accessed October 25, 2023. https://www.businesswire.com/news/home/20231019250308/en/Massive-Bio-and-ONCOassist%C2%AE-Announce-Strategic-Partnership-at-ESMO-2023
Advertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Where AI Governance in Clinical Development Falls Short
4
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
5